• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Bio-Rad Reports Third-Quarter 2024 Financial Results

    10/30/24 4:15:00 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BIO alert in real time by email

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2024.

    Third-quarter 2024 total net sales were $649.7 million, an increase of 2.8 percent compared to $632.1 million reported for the third quarter of 2023. On a currency-neutral basis, quarterly sales increased 3.4 percent compared to the same period in 2023. The increase in net sales was driven by higher sales in our Clinical Diagnostics segment.

    Life Science segment net sales for the third quarter were $260.9 million, a decrease of 1.0 percent compared to the same period in 2023. On a currency-neutral basis, sales decreased by 0.6 percent compared to the same quarter in 2023, driven by ongoing weakness in the biotech and biopharma end markets. Currency neutral sales decreased in the Americas, offset by increases in EMEA.

    Clinical Diagnostics segment net sales for the third quarter were $388.8 million, an increase of 5.6 percent compared to the same period in 2023. On a currency-neutral basis, sales increased 6.4 percent compared to the same quarter last year. The currency neutral sales increase was primarily driven by increased demand for quality control products, and a favorable compare for our immunology products, which were impacted by supply constraints in the third quarter of 2023. Currency neutral sales increased across all regions.

    Third-quarter gross margin was 54.8 percent compared to 53.1 percent during the third quarter of 2023.

    Income from operations during the third quarter of 2024 was $64.5 million versus $90.9 million during the same quarter last year.

    During the third quarter of 2024, the company recognized a change in the fair market value of its investment in Sartorius AG, which substantially contributed to a net income of $653.2 million, or $23.34 per share, on a diluted basis, versus a net income of $106.3 million, or $3.64 per share, on a diluted basis, reported for the same period of 2023.

    The effective tax rate for the third quarter of 2024 was 24.2 percent, compared to 22.5 percent for the same period in 2023. The effective tax rate reported in these periods was primarily affected by the accounting treatment of our equity securities.

    "Our third-quarter revenue performance was slightly ahead of expectations, driven by steady growth in clinical diagnostics products, while our life science business continued to improve reflecting a gradual recovery in the biopharma end market," said Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer. "During the quarter, we also welcomed Jon DiVincenzo as President and Chief Operating Officer. Jon joins Bio-Rad's other recently hired senior executives who collectively bring a wealth of life science, clinical diagnostics, and operations experience. With the new senior leadership team in place, we are focused on margin expansion, commercial excellence, and creating long-term shareholder value."

    The non-GAAP financial measures discussed below exclude certain items detailed later in this press release under the heading "Use of Non-GAAP and Currency-Neutral Reporting." A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.

    Non-GAAP gross margin was 55.6 percent for the third quarter of 2024 compared to 53.9 percent during the third quarter of 2023.

    Non-GAAP income from operations during the third quarter of 2024 was $73.3 million versus $81.6 million during the comparable prior-year period.

    Non-GAAP net income for the third quarter of 2024 was $56.4 million, or $2.01 per share, on a diluted basis, compared to $68.1 million, or $2.33 per share, on a diluted basis, during the same period in 2023.

    The non-GAAP effective tax rate for the third quarter of 2024 was 28.8 percent, compared to 23.9 percent for the same period in 2023. The higher rate in 2024 was driven by geographical mix of earnings and a one-time acquired in-process research and development expense.

    GAAP Results

     

    Q3 2024

    Q3 2023

    Revenue (millions)

    $

    649.7

     

    $

    632.1

     

    Gross margin

     

    54.8

    %

     

    53.1

    %

    Operating margin

     

    9.9

    %

     

    14.4

    %

    Net income (millions)

    $

    653.2

     

    $

    106.3

     

    Income per diluted share

    $

    23.34

     

    $

    3.64

     

     

    Non-GAAP Results

     

    Q3 2024

    Q3 2023

    Revenue (millions)

    $

    649.7

     

    $

    632.1

     

    Gross margin

     

    55.6

    %

     

    53.9

    %

    Operating margin

     

    11.3

    %

     

    12.9

    %

    Net income (millions)

    $

    56.4

     

    $

    68.1

     

    Income per diluted share

    $

    2.01

     

    $

    2.33

     

    Updated Full-Year 2024 Financial Outlook

    Bio-Rad continues to expect its non-GAAP revenue to decline by approximately 2.5 to 4.0 percent on a currency-neutral basis. The company estimates a non-GAAP operating margin of between 12.75 to 13.25 percent, which now also includes the impact of a one-time acquired in-process research and development expense related to an acquisition completed during the third quarter.

    Conference Call and Webcast

    Management will discuss the company's third quarter 2024 results and financial outlook in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) on October 30, 2024. To participate, dial 800-579-2543 within the U.S., or (+1) 785-424-1789 from outside the U.S., and provide access code: BIORAD.

    A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for up to a year.

    Use of Non-GAAP and Currency-Neutral Reporting

    In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including non-GAAP net income and non-GAAP EPS, which exclude amortization of acquisition-related intangible assets, certain acquisition-related expenses and benefits, restructuring charges, asset impairment charges, gains and losses from change in fair market value of equity securities and loan receivable, gains and losses on equity-method investments, and significant legal-related charges or benefits and associated legal costs. Non-GAAP net income and non-GAAP EPS also exclude certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, tax provisions/benefits related to the previous items, and significant discrete tax events. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.

    We utilize a number of different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of our business, in making operating decisions, forecasting and planning for future periods, and determining payments under compensation programs. We consider the use of the non-GAAP measures to be helpful in assessing the performance of the ongoing operation of our business. We believe that disclosing non-GAAP financial measures provides useful supplemental data that, while not a substitute for financial measures prepared in accordance with GAAP, allows for greater transparency in the review of our financial and operational performance. We also believe that disclosing non-GAAP financial measures provides useful information to investors and others in understanding and evaluating our operating results and future prospects in the same manner as management and in comparing financial results across accounting periods and to those of peer companies. More specifically, management adjusts for the excluded items for the following reasons:

    Amortization of purchased intangible assets: we do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to purchased intangible assets and the term of amortization can vary significantly and are unique to each acquisition or purchase. We believe that excluding amortization of purchased intangible assets allows the users of our financial statements to better review and understand the historic and current results of our operations, and also facilitates comparisons to peer companies.

    Acquisition-related expenses and benefits: we incur expenses or benefits with respect to certain items associated with our acquisitions, such as transaction costs, professional fees for assistance with the transaction; valuation or integration costs; changes in the fair value of contingent consideration, gain or loss on settlement of pre-existing relationships with the acquired entity; or adjustments to purchase price. We exclude such expenses or benefits as they are related to acquisitions and have no direct correlation to the operation of our on-going business.

    Restructuring, impairment charges, and gains and losses from change in fair market value of equity securities and loan receivable, and gains and losses on equity-method investments: we incur restructuring and impairment charges on individual or groups of employed assets and charges and benefits arising from gains and losses from change in fair market value of equity securities and loan receivable, and gains and losses (including impairments) on equity-method investments, which arise from unforeseen circumstances and/or often occur outside of the ordinary course of our on-going business. Although these events are reflected in our GAAP financials, these unique transactions may limit the comparability of our on-going operations with prior and future periods.

    Significant litigation charges or benefits and legal costs: we may incur charges or benefits as well as legal costs in connection with litigation and other contingencies unrelated to our core operations. We exclude these charges or benefits, when significant, as well as legal costs associated with significant legal matters, because we do not believe they are reflective of on-going business and operating results.

    Income tax expense: we estimate the tax effect of the excluded items identified above to determine a non-GAAP annual effective tax rate applied to the pretax amount in order to calculate the non-GAAP provision for income taxes. We also adjust for items for which the nature and/or tax jurisdiction requires the application of a specific tax rate or treatment.

    From time to time in the future, there may be other items excluded if we believe that doing so is consistent with the goal of providing useful information to investors and management.

    Percentage sales growth in currency neutral amounts are calculated by translating prior period sales in each local currency using the current period's monthly average foreign exchange rates for that currency and comparing that to current period sales.

    There are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact on our reported financial results. The presentation of this additional information is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP in the United States. Investors should review the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this press release.

    We do not provide a reconciliation of our non-GAAP financial expectations to expectations for the most comparable GAAP measure because the amount and timing of many future charges that impact these measures (such as amortization of future acquisition-related intangible assets, future acquisition-related expenses and benefits, future restructuring charges, future asset impairment charges, future valuation changes of equity-owned securities, future gains and losses on equity-method investments or future legal charges or benefits), which could be material, are variable, uncertain, or out of our control and therefore cannot be reasonably predicted without unreasonable effort, if at all.

    BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions.

    About Bio-Rad

    Bio-Rad Laboratories, Inc. (NYSE:BIO) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,700 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.

    Forward-Looking Statements

    This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding estimated future financial performance or results; being focused on margin expansion, commercial excellence, and creating long-term shareholder value; and for the full-year 2024: continuing to expect non-GAAP revenue to decline by approximately 2.5 to 4.0 percent on a currency-neutral basis and estimating a non-GAAP operating margin of between 12.75 to 13.25 percent. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "expect," "estimate," "continue," "believe," "anticipate," "target," "will," "project," "assume," "may," "intend," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include reductions in government funding or capital spending of our customers, global economic and geopolitical conditions, the uncertain pace of the biopharma sector's recovery, the challenging macroeconomic environment in China, supply chain issues, international legal and regulatory risks, our ability to develop and market new or improved products, our ability to compete effectively, foreign currency exchange fluctuations, product quality and liability issues, our ability to integrate acquired companies, products or technologies into our company successfully, changes in the healthcare industry, and natural disasters and other catastrophic events beyond our control. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's public reports filed with the Securities and Exchange Commission (the "SEC"), including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 to be filed with the SEC. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.

    Bio-Rad Laboratories, Inc.

    Condensed Consolidated Statements of Income (Loss)

    (In thousands, except per share data)

    (Unaudited)

     

     

     

     

     

     

     

     

     

     

     

    Three Months Ended

     

    Nine Months Ended

     

     

    September 30,

     

    September 30,

     

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    Net sales

    $

    649,729

     

    $

    632,124

     

    $

    1,899,025

     

    $

    1,990,078

     

    Cost of goods sold

     

    293,826

     

     

    296,441

     

     

    862,037

     

     

    929,495

     

    Gross profit

     

    355,903

     

     

    335,683

     

     

    1,036,988

     

     

    1,060,583

     

    Selling, general and administrative expense

     

    200,440

     

     

    201,199

     

     

    610,042

     

     

    634,576

     

    Research and development expense

     

    90,997

     

     

    43,535

     

     

    216,276

     

     

    183,528

     

    Income from operations

     

    64,466

     

     

    90,949

     

     

    210,670

     

     

    242,479

     

    Interest expense

     

    12,174

     

     

    12,398

     

     

    36,715

     

     

    37,078

     

    Foreign currency exchange (gains) losses, net

     

    1,641

     

     

    (1,680

    )

     

    (2,012

    )

     

    (5,280

    )

    (Gains) losses from change in fair market value of equity
    securities and loan receivable

     

    (792,888

    )

     

    (36,425

    )

     

    1,680,290

     

     

    1,576,542

     

    Other income, net

     

    (18,081

    )

     

    (20,446

    )

     

    (70,740

    )

     

    (87,365

    )

    Income (loss) before income taxes

     

    861,620

     

     

    137,102

     

     

    (1,433,583

    )

     

    (1,278,496

    )

    (Provision for) benefit from income taxes

     

    (208,448

    )

     

    (30,845

    )

     

    305,185

     

     

    291,464

     

    Net income (loss)

    $

    653,172

     

    $

    106,257

     

    $

    (1,128,398

    )

    $

    (987,032

    )

     
    Basic earnings (loss) per share:
    Net income (loss) per basic share

    $

    23.37

     

    $

    3.65

     

    $

    (39.89

    )

    $

    (33.63

    )

    Weighted average common shares - basic

     

    27,949

     

     

    29,102

     

     

    28,286

     

     

    29,349

     

     
    Diluted earnings (loss) per share:
    Net income (loss) per diluted share

    $

    23.34

     

    $

    3.64

     

    $

    (39.89

    )

    $

    (33.63

    )

    Weighted average common shares - diluted

     

    27,985

     

     

    29,223

     

     

    28,286

     

     

    29,349

      Note:   As a result of the net loss for the nine months ended September 30, 2024 and 2023,
        all potentially issuable common shares have been excluded from the diluted shares
        used in the computation of earnings per share as their effect was anti-dilutive.

    Bio-Rad Laboratories, Inc.

    Condensed Consolidated Balance Sheets

    (In thousands)

     

     

     

     

     

    September 30,

     

    December 31,

     

    2024

     

    2023

     

    (Unaudited)

     

     

    Current assets:
    Cash and cash equivalents

    $

    410,377

    $

    403,815

    Short-term investments

     

    1,217,641

     

    1,208,887

    Accounts receivable, net

     

    461,940

     

    489,017

    Inventories, net

     

    804,276

     

    780,517

    Other current assets

     

    161,386

     

    166,094

    Total current assets

     

    3,055,620

     

    3,048,330

     
    Property, plant and equipment, net

     

    545,304

     

    529,007

    Operating lease right-of-use assets

     

    173,866

     

    194,730

    Goodwill, net

     

    415,100

     

    413,569

    Purchased intangibles, net

     

    307,325

     

    320,514

    Other investments

     

    6,002,635

     

    7,698,070

    Other assets

     

    103,622

     

    94,850

    Total assets

    $

    10,603,472

    $

    12,299,070

     
    Current liabilities:
    Accounts payable, accrued payroll and employee benefits

    $

    268,209

    $

    284,554

    Current maturities of long-term debt

     

    1,262

     

    486

    Income and other taxes payable

     

    43,625

     

    35,759

    Other current liabilities

     

    184,847

     

    202,000

    Total current liabilities

     

    497,943

     

    522,799

     
    Long-term debt, net of current maturities

     

    1,200,062

     

    1,199,052

    Other long-term liabilities

     

    1,417,608

     

    1,836,086

    Total liabilities

     

    3,115,613

     

    3,557,937

     
    Total stockholders' equity

     

    7,487,859

     

    8,741,133

    Total liabilities and stockholders' equity

    $

    10,603,472

    $

    12,299,070

    Bio-Rad Laboratories, Inc.

    Condensed Consolidated Statements of Cash Flows

    (In thousands)

    (Unaudited)

     

     

     

     

     

    Nine Months Ended

     

    September 30,

     

     

    2024

     

     

     

    2023

     

     
    Cash flows from operating activities:
    Cash received from customers

    $

    1,920,985

     

    $

    2,007,482

     

    Cash paid to suppliers and employees

     

    (1,531,330

    )

     

    (1,722,173

    )

    Interest paid, net

     

    (45,628

    )

     

    (46,394

    )

    Income tax payments, net

     

    (75,710

    )

     

    (40,966

    )

    Other operating activities

     

    62,731

     

     

    95,947

     

    Net cash provided by operating activities

     

    331,048

     

     

    293,896

     

     
    Cash flows from investing activities:
    Payments for purchases of marketable securities and investments

     

    (1,053,660

    )

     

    (537,540

    )

    Proceeds from sales and maturities of marketable securities and
    investments

     

    1,069,951

     

     

    599,882

     

    Other investing activities

     

    (145,947

    )

     

    (114,331

    )

    Net cash used in investing activities

     

    (129,656

    )

     

    (51,989

    )

     
    Cash flows from financing activities:
    Payments on long-term debt

     

    (359

    )

     

    (349

    )

    Other financing activities

     

    (192,193

    )

     

    (224,678

    )

    Net cash used in financing activities

     

    (192,552

    )

     

    (225,027

    )

     
    Effect of foreign exchange rate changes on cash

     

    (1,021

    )

     

    6,891

     

     
    Net increase in cash, cash equivalents and restricted cash

     

    7,819

     

     

    23,771

     

    Cash, cash equivalents and restricted cash at beginning of period

     

    404,369

     

     

    434,544

     

    Cash, cash equivalents and restricted cash at end of period

    $

    412,188

     

    $

    458,315

     

     
     
    Reconciliation of net loss to net cash provided by operating activities:
    Net loss

    $

    (1,128,398

    )

    $

    (987,032

    )

    Adjustments to reconcile net loss to net cash provided by operating activities:
    Depreciation and amortization

     

    112,393

     

     

    108,724

     

    Reduction in the carrying amount of right-of-use assets

     

    31,066

     

     

    30,725

     

    Losses from change in fair market value of equity securities and loan receivable

     

    1,680,290

     

     

    1,576,542

     

    Changes in working capital

     

    (29,950

    )

     

    (61,623

    )

    Other

     

    (334,353

    )

     

    (373,440

    )

    Net cash provided by operating activities

    $

    331,048

     

    $

    293,896

     

    Bio-Rad Laboratories, Inc.
    Reconciliation of GAAP financial measures to non-GAAP financial measures
    (In thousands, except per share data)
    (Unaudited)

    In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including non-GAAP net income and non-GAAP diluted income per share (non-GAAP EPS), which exclude amortization of acquisition-related intangible assets; certain acquisition-related expenses and benefits; restructuring charges; asset impairment charges; gains and losses from change in fair market value of equity securities and loan receivable; gains and losses on equity-method investments; and significant legal-related charges or benefits and associated legal costs. Non-GAAP net income and non-GAAP EPS also exclude certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, tax provisions/benefits related to the previous items, and significant discrete tax events. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.

    We utilize a number of different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of our business, in making operating decisions, forecasting and planning for future periods, and determining payments under compensation programs. We consider the use of the non-GAAP measures to be helpful in assessing the performance of the ongoing operation of our business. We believe that disclosing non-GAAP financial measures provides useful supplemental data that, while not a substitute for financial measures prepared in accordance with GAAP, allows for greater transparency in the review of our financial and operational performance. We also believe that disclosing non-GAAP financial measures provides useful information to investors and others in understanding and evaluating our operating results and future prospects in the same manner as management and in comparing financial results across accounting periods and to those of peer companies.

    Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended
    September 30, % of September 30, % of September 30, % of September 30, % of

     

    2024

     

    revenue

     

    2023

     

    revenue

     

    2024

     

    revenue

     

    2023

     

    revenue
     
    GAAP cost of goods sold

    $

    293,826

     

    $

    296,441

     

    $

    862,037

     

    $

    929,495

     

    Amortization of purchased intangibles

     

    (4,499

    )

     

    (4,507

    )

     

    (13,391

    )

     

    (13,131

    )

    Restructuring benefits (costs)

     

    (603

    )

     

    (215

    )

     

    (1,764

    )

     

    (3,922

    )

    Non-GAAP cost of goods sold

    $

    288,724

     

    $

    291,719

     

    $

    846,882

     

    $

    912,442

     

     
    GAAP gross profit

    $

    355,903

     

    54.8

    %

    $

    335,683

     

    53.1

    %

    $

    1,036,988

     

    54.6

    %

    $

    1,060,583

     

    53.3

    %

    Amortization of purchased intangibles

     

    4,499

     

     

    4,507

     

     

    13,391

     

     

    13,131

     

    Restructuring (benefits) costs

     

    603

     

     

    215

     

     

    1,764

     

     

    3,922

     

    Non-GAAP gross profit

    $

    361,005

     

    55.6

    %

    $

    340,405

     

    53.9

    %

    $

    1,052,143

     

    55.4

    %

    $

    1,077,636

     

    54.2

    %

     
    GAAP selling, general and administrative expense

    $

    200,440

     

    $

    201,199

     

    $

    610,042

     

    $

    634,576

     

    Amortization of purchased intangibles

     

    (825

    )

     

    (1,629

    )

     

    (2,686

    )

     

    (4,931

    )

    Acquisition related benefits (costs)

     

    -

     

     

    4,100

     

     

    -

     

     

    4,100

     

    Restructuring benefits (costs)

     

    (819

    )

     

    (1,339

    )

     

    (3,825

    )

     

    (16,655

    )

    Other non-recurring items (2)

     

    (1,663

    )

     

    (1,877

    )

     

    (4,704

    )

     

    (5,794

    )

    Non-GAAP selling, general and administrative expense

    $

    197,133

     

    $

    200,454

     

    $

    598,827

     

    $

    611,296

     

     
    GAAP research and development expense

    $

    90,997

     

    $

    43,535

     

    $

    216,276

     

    $

    183,528

     

    Acquisition related benefits (costs)

     

    (400

    )

     

    14,800

     

     

    (800

    )

     

    14,400

     

    Restructuring benefits (costs)

     

    (19

    )

     

    22

     

     

    (1,519

    )

     

    (5,293

    )

    Non-GAAP research and development expense

    $

    90,578

     

    $

    58,357

     

    $

    213,957

     

    $

    192,635

     

     
    GAAP income from operations

    $

    64,466

     

    9.9

    %

    $

    90,949

     

    14.4

    %

    $

    210,670

     

    11.1

    %

    $

    242,479

     

    12.2

    %

    Amortization of purchased intangibles

     

    5,324

     

     

    6,136

     

     

    16,077

     

     

    18,062

     

    Acquisition related (benefits) costs

     

    400

     

     

    (18,900

    )

     

    800

     

     

    (18,500

    )

    Restructuring (benefits) costs

     

    1,441

     

     

    1,532

     

     

    7,108

     

     

    25,870

     

    Other non-recurring items (2)

     

    1,663

     

     

    1,877

     

     

    4,704

     

     

    5,794

     

    Non-GAAP income from operations

    $

    73,294

     

    11.3

    %

    $

    81,594

     

    12.9

    %

    $

    239,359

     

    12.6

    %

    $

    273,705

     

    13.8

    %

     
    GAAP (gains) losses from change in fair market value of equity securities and loan receivable

    $

    (792,888

    )

    $

    (36,425

    )

    $

    1,680,290

     

    $

    1,576,542

     

    Gains (losses) from change in fair market value of equity securities and loan receivable

     

    792,888

     

     

    36,425

     

     

    (1,680,290

    )

     

    (1,576,542

    )

    Non-GAAP (gains) losses from change in fair market value of equity securities and loan receivable

    $

    -

     

    $

    -

     

    $

    -

     

    $

    -

     

     
    GAAP other (income) expense, net

    $

    (18,081

    )

    $

    (20,446

    )

    $

    (70,740

    )

    $

    (87,365

    )

    Gains (losses) on equity-method investments

     

    (1,626

    )

     

    (697

    )

     

    (3,349

    )

     

    (2,543

    )

    Other non-recurring items (3)

     

    -

     

     

    2,500

     

     

    -

     

     

    2,500

     

    Non-GAAP other (income) expense, net

    $

    (19,707

    )

    $

    (18,643

    )

    $

    (74,089

    )

    $

    (87,408

    )

     
    GAAP income (loss) before income taxes

    $

    861,620

     

    $

    137,102

     

    $

    (1,433,583

    )

    $

    (1,278,496

    )

    Amortization of purchased intangibles

     

    5,324

     

     

    6,136

     

     

    16,077

     

     

    18,062

     

    Acquisition related (benefits) costs

     

    400

     

     

    (18,900

    )

     

    800

     

     

    (18,500

    )

    Restructuring (benefits) costs

     

    1,441

     

     

    1,532

     

     

    7,108

     

     

    25,870

     

    (Gains) losses from change in fair market value of equity securities and loan receivable

     

    (792,888

    )

     

    (36,425

    )

     

    1,680,290

     

     

    1,576,542

     

    (Gains) losses on equity-method investments

     

    1,626

     

     

    697

     

     

    3,349

     

     

    2,543

     

    Other non-recurring items (2) (3)

     

    1,663

     

     

    (623

    )

     

    4,704

     

     

    3,294

     

    Non-GAAP income before income taxes

    $

    79,186

     

    $

    89,519

     

    $

    278,745

     

    $

    329,315

     

     
    GAAP (provision for) benefit from income taxes

    $

    (208,448

    )

    $

    (30,845

    )

    $

    305,185

     

    $

    291,464

     

    Income tax effect of non-GAAP adjustments (1)

     

    185,624

     

     

    9,408

     

     

    (373,835

    )

     

    (364,826

    )

    Non-GAAP provision for income taxes

    $

    (22,824

    )

    $

    (21,437

    )

    $

    (68,650

    )

    $

    (73,362

    )

     
    GAAP net income (loss)

    $

    653,172

     

    100.5

    %

    $

    106,257

     

    16.8

    %

    $

    (1,128,398

    )

    (59.4

    )%

    $

    (987,032

    )

    (49.6

    )%

    Amortization of purchased intangibles

     

    5,324

     

     

    6,136

     

     

    16,077

     

     

    18,062

     

    Acquisition related (benefits) costs

     

    400

     

     

    (18,900

    )

     

    800

     

     

    (18,500

    )

    Restructuring (benefits) costs

     

    1,441

     

     

    1,532

     

     

    7,108

     

     

    25,870

     

    (Gains) losses from change in fair market value of equity securities and loan receivable

     

    (792,888

    )

     

    (36,425

    )

     

    1,680,290

     

     

    1,576,542

     

    (Gains) losses on equity-method investments

     

    1,626

     

     

    697

     

     

    3,349

     

     

    2,543

     

    Other non-recurring items (2) (3)

     

    1,663

     

     

    (623

    )

     

    4,704

     

     

    3,294

     

    Income tax effect of non-GAAP adjustments (1)

     

    185,624

     

     

    9,408

     

     

    (373,835

    )

     

    (364,826

    )

    Non-GAAP net income

    $

    56,362

     

    8.7

    %

    $

    68,082

     

    10.8

    %

    $

    210,095

     

    11.1

    %

    $

    255,953

     

    12.9

    %

     
    GAAP diluted income (loss) per share

    $

    23.34

     

    $

    3.64

     

    $

    (39.89

    )

    $

    (33.63

    )

    Amortization of purchased intangibles

     

    0.19

     

     

    0.21

     

     

    0.57

     

     

    0.61

     

    Acquisition related (benefits) costs

     

    0.01

     

     

    (0.65

    )

     

    0.03

     

     

    (0.63

    )

    Restructuring (benefits) costs

     

    0.05

     

     

    0.05

     

     

    0.25

     

     

    0.88

     

    (Gains) losses from change in fair market value of equity securities and loan receivable

     

    (28.33

    )

     

    (1.25

    )

     

    59.35

     

     

    53.47

     

    (Gains) losses on equity-method investments

     

    0.06

     

     

    0.02

     

     

    0.12

     

     

    0.09

     

    Other non-recurring items (2) (3)

     

    0.06

     

     

    (0.02

    )

     

    0.17

     

     

    0.11

     

    Income tax effect of non-GAAP adjustments (1)

     

    6.63

     

     

    0.33

     

     

    (13.21

    )

     

    (12.38

    )

    Add back anti-dilutive shares

     

    -

     

     

    -

     

     

    0.03

     

     

    0.16

     

    Non-GAAP diluted income per share

    $

    2.01

     

    $

    2.33

     

    $

    7.42

     

    $

    8.68

     

     
    GAAP diluted weighted average shares used in per share calculation

     

    27,985

     

     

    29,223

     

     

    28,286

     

     

    29,349

     

    Shares included in non-GAAP net income per share, but excluded from GAAP net loss per share as they would have been anti-dilutive

     

    -

     

     

    -

     

     

    24

     

     

    137

     

    Non-GAAP diluted weighted average shares used in per share calculation

     

    27,985

     

     

    29,223

     

     

    28,310

     

     

    29,486

     

     
    Reconciliation of net income (loss) to adjusted EBITDA:
    GAAP net income (loss)

    $

    653,172

     

    100.5

    %

    $

    106,257

     

    16.8

    %

    $

    (1,128,398

    )

    (59.4

    )%

    $

    (987,032

    )

    (49.6

    )%

    Interest expense

     

    12,174

     

     

    12,398

     

     

    36,715

     

     

    37,078

     

    (Provision for) benefit from income taxes

     

    208,448

     

     

    30,845

     

     

    (305,185

    )

     

    (291,464

    )

    Depreciation and amortization

     

    38,891

     

     

    37,278

     

     

    112,393

     

     

    108,724

     

    Foreign currency exchange (gains) losses, net

     

    1,641

     

     

    (1,680

    )

     

    (2,012

    )

     

    (5,280

    )

    Other income, net

     

    (18,081

    )

     

    (20,446

    )

     

    (70,740

    )

     

    (87,365

    )

    (Gains) losses from change in fair market value of equity securities and loan receivable

     

    (792,888

    )

     

    (36,425

    )

     

    1,680,290

     

     

    1,576,542

     

    Dividend from Sartorius AG

     

    -

     

     

    -

     

     

    17,930

     

     

    34,766

     

    Acquisition related (benefits) costs

     

    400

     

     

    (18,900

    )

     

    800

     

     

    (18,500

    )

    Restructuring (benefits) costs

     

    1,441

     

     

    1,532

     

     

    7,108

     

     

    25,870

     

    Other non-recurring items (2)

     

    1,663

     

     

    1,877

     

     

    4,704

     

     

    5,794

     

    Adjusted EBITDA

    $

    106,861

     

    16.4

    %

    $

    112,736

     

    17.8

    %

    $

    353,605

     

    18.6

    %

    $

    399,133

     

    20.1

    %

    (1)

      Excluded items identified in the reconciliation schedule are tax effected by application of a non-GAAP effective tax rate. The non-GAAP tax
        provision is adjusted for items, the nature of which and/or tax jurisdiction requires the application of a specific tax rate or treatment.

    (2)

      Incremental costs to comply with the European Union's In Vitro Diagnostics Regulation ("IVDR") for previously approved products.

    (3)

      Gain from the release of an escrow for the acquisition in 2021 (2023).

    2024 Financial Outlook

    Forecasted non-GAAP operating margin excludes 85 basis points related to amortization of purchased intangibles. Forecasted non-GAAP operating margin does not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance, such as foreign currency fluctuations, future gains or losses associated with certain legal matters, acquisitions and restructuring activities. We do not provide a reconciliation of our non-GAAP financial expectations to expectations for the most comparable GAAP measure because the amount and timing of many future charges that impact these measures (such as amortization of future acquisition-related intangible assets, future acquisition-related expenses and benefits, future restructuring charges, future asset impairment charges, future valuation changes of equity-owned securities, future gains and losses on equity-method investments or future legal charges or benefits), which could be material, are variable, uncertain, or out of our control and therefore cannot be reasonably predicted without unreasonable effort, if at all.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241030533020/en/

    Get the next $BIO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BIO

    DatePrice TargetRatingAnalyst
    10/1/2024$350.00 → $400.00Neutral → Buy
    Citigroup
    8/28/2024$340.00Equal Weight
    Wells Fargo
    6/3/2024$315.00Hold
    Jefferies
    4/3/2024$400.00 → $365.00Buy → Neutral
    Citigroup
    12/7/2023$395.00Buy
    UBS
    6/16/2023$550.00Overweight
    Wells Fargo
    12/7/2022$565.00Outperform
    RBC Capital Mkts
    8/25/2022$715.00Outperform
    Credit Suisse
    More analyst ratings

    $BIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference

      Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Operating Officer Jon DiVincenzo will host one-on-one meetings with investors during the Jefferies Global Healthcare Conference in New York City, on June 4, 2025. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE:BIO) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 7,500 employees, and $2.6 billion in reve

      5/29/25 4:30:00 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference

      Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 1:35 PM Eastern Time (10:35 AM Pacific Time). A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad's website at bio-rad.com. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE:BIO) is a leader in developing, manufacturing, and marketing a broad range of products for the life

      5/12/25 4:30:00 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bio-Rad Reports First-Quarter 2025 Financial Results

      Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2025. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: "We navigated a highly dynamic first quarter that became progressively more challenging, yet we delivered solid margins through focused execution and careful expense management. Given the current levels of market uncertainty, we are moderating our full-year 2025 outlook to reflect the evolving macro environment. Going forward, we remain committed to advancing our growth and margin expansion initiatives." Financial Results Highl

      5/1/25 4:15:00 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bio-Rad Labs upgraded by Citigroup with a new price target

      Citigroup upgraded Bio-Rad Labs from Neutral to Buy and set a new price target of $400.00 from $350.00 previously

      10/1/24 7:11:23 AM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Wells Fargo initiated coverage on Bio-Rad Labs with a new price target

      Wells Fargo initiated coverage of Bio-Rad Labs with a rating of Equal Weight and set a new price target of $340.00

      8/28/24 7:34:48 AM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Jefferies resumed coverage on Bio-Rad Labs with a new price target

      Jefferies resumed coverage of Bio-Rad Labs with a rating of Hold and set a new price target of $315.00

      6/3/24 8:40:37 AM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider May Simon claimed ownership of 43 units of Bio-Rad A Common Stock

      3 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)

      1/7/22 1:09:06 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4: Wright Dara converted options into 502 units of Bio-Rad A Common Stock and covered exercise/tax liability with 221 units of Bio-Rad A Common Stock, increasing direct ownership by 46% to 892 units

      4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)

      12/17/21 2:21:01 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4: Schwartz Norman D received a gift of 40 units of Bio-Rad B Common Stock, increasing direct ownership by 0.01% to 316,146 units

      4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)

      11/23/21 2:30:23 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BIO
    SEC Filings

    See more
    • Bio-Rad Laboratories, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)

      11/18/21 4:46:00 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 10-Q filed by Bio-Rad Laboratories, Inc.

      10-Q - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)

      10/29/21 4:06:54 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bio-Rad Laboratories, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)

      10/28/21 4:27:41 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

      9/6/24 6:43:00 PM ET
      $AAL
      $ADMA
      $ADNT
      $AMCX
      Air Freight/Delivery Services
      Consumer Discretionary
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer

      Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that Jon DiVincenzo will join the company as President and Chief Operating Officer, effective September 9, 2024, replacing Andy Last, who is retiring. Mr. DiVincenzo joins Bio-Rad from Labcorp Holdings Inc., a global provider of comprehensive laboratory services, where he held various global operational and commercial leadership roles across the company's several business units. Most recently, he served as Executive Vice President and President, Central Laboratories and International. Prior to LabCorp, Mr. DiVincenzo was President of the Environmental Health D

      8/20/24 8:30:00 AM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer

      Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that Roop K. Lakkaraju will join the company as its new Executive Vice President and Chief Financial Officer, effective April 15, 2024. Mr. Lakkaraju joins Bio-Rad from Benchmark Electronics, a multi-national leader in electronics manufacturing services, where he served as Executive Vice President and Chief Financial Officer responsible for all finance-related functions supporting the company's global operations since 2018. Prior to Benchmark, he held Chief Financial Officer and senior operational roles at several large, multinational companies including Suppo

      3/20/24 8:30:00 AM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BIO
    Financials

    Live finance-specific insights

    See more
    • Bio-Rad Reports First-Quarter 2025 Financial Results

      Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2025. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: "We navigated a highly dynamic first quarter that became progressively more challenging, yet we delivered solid margins through focused execution and careful expense management. Given the current levels of market uncertainty, we are moderating our full-year 2025 outlook to reflect the evolving macro environment. Going forward, we remain committed to advancing our growth and margin expansion initiatives." Financial Results Highl

      5/1/25 4:15:00 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

      Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2025 on Thursday, May 1, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:30 PM Pacific Time (5:30 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available

      4/15/25 4:15:00 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results

      Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2024. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, commented: "Bio-Rad demonstrated resilience and adaptability in 2024. While the biopharma headwinds dampened our Life Science segment results, our Clinical Diagnostics business returned to a more normalized growth rate, and our ongoing transformation initiatives and diligent cost management helped improve our gross margins." Mr. Schwartz continued: "We begin 2025 in a strong position and remain committed to advancing

      2/13/25 4:20:00 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed

      SC 13G/A - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)

      2/10/21 10:39:36 AM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed

      SC 13G - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)

      2/8/21 10:17:35 AM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials